First PREMIER Bank trimmed its position in Johnson & Johnson (NYSE:JNJ) by 2.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,110 shares of the company’s stock after selling 1,323 shares during the period. Johnson & Johnson makes up approximately 3.1% of First PREMIER Bank’s holdings, making the stock its 5th biggest holding. First PREMIER Bank’s holdings in Johnson & Johnson were worth $5,965,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Billeaud Capital Management Inc. increased its position in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock valued at $6,130,000 after purchasing an additional 169 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in Johnson & Johnson by 11.1% during the 2nd quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock worth $15,277,000 after purchasing an additional 10,927 shares during the period. Archford Capital Strategies LLC boosted its stake in Johnson & Johnson by 11.2% during the 2nd quarter. Archford Capital Strategies LLC now owns 21,997 shares of the company’s stock worth $3,064,000 after purchasing an additional 2,211 shares during the period. Marino Stram & Associates LLC boosted its stake in Johnson & Johnson by 1.2% during the 2nd quarter. Marino Stram & Associates LLC now owns 32,199 shares of the company’s stock worth $4,485,000 after purchasing an additional 380 shares during the period. Finally, Palisades Hudson Asset Management L.P. boosted its stake in Johnson & Johnson by 42.6% during the 2nd quarter. Palisades Hudson Asset Management L.P. now owns 2,241 shares of the company’s stock worth $312,000 after purchasing an additional 669 shares during the period. Institutional investors own 72.01% of the company’s stock.
Shares of JNJ stock traded up $2.76 during mid-day trading on Friday, hitting $131.82. The stock had a trading volume of 1,750,647 shares, compared to its average volume of 6,702,304. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The firm has a market cap of $347.95 billion, a PE ratio of 16.11, a PEG ratio of 2.22 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The company’s 50-day simple moving average is $129.92 and its 200-day simple moving average is $135.00.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company had revenue of $20.56 billion during the quarter, compared to analysts’ expectations of $20.39 billion. During the same quarter last year, the business earned $2.10 EPS. The business’s revenue was down 1.3% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 8.59 EPS for the current year.
Several research firms have recently commented on JNJ. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a research note on Thursday, July 18th. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Finally, Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Friday. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $151.00.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What Are Cryptocurrencies?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.